{"entity":{"id":"nct07565285","kind":"trial","name":"The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma","aka":["INFLECTION-003"],"tldr":"A phase 2 trial of Pembrolizumab in melanoma, run by Primmune Therapeutics, Inc., now recruiting.","summary":"The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma is a phase 2 interventional study registered as NCT07565285 by Primmune Therapeutics, Inc., with 48 participants planned, started 2026-07-01 and due to reach its primary completion in 2027-12. Interventions recorded: PRTX007, Pembrolizumab. Conditions listed: Melanoma Stage III. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07565285","url":"https://clinicaltrials.gov/study/NCT07565285"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","stage-iii-melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab","prtx007"],"companies":["primmune-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07565285","phase":"2","setting":"A Phase 2 Study to Investigate the Activity of Neoadjuvant PRTX007 Combined With Pembrolizumab in Participants With Stage III Melanoma (INFLECTION-003)","sponsor":"Primmune Therapeutics, Inc.","started":"2026-07-01","startedType":"actual","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07565285/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"prtx007","kind":"drug","name":"PRTX007","route":"/drugs/prtx007/"}],"company":[{"id":"primmune-therapeutics","kind":"company","name":"Primmune Therapeutics","route":"/companies/primmune-therapeutics/"}]}}